Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006482 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00006482: Clinical Trial Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00006482 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006482, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and cisplatin in treating patients who have refractory or recurrent cancer of the cervix.
Interventions
- DRUG cisplatin
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Phase | Phase 2 |
Why NCT00006482 stopped before completion
NCT00006482 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00006482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006482 about?
NCT00006482 is a clinical study titled "Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and cisplatin in treating patients who have ref...
What is the current status of trial NCT00006482?
This trial is currently terminated. It is a Phase 2 study. The study started on 2000-10.
What interventions are being tested in trial NCT00006482?
The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006482?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia